Trial Outcomes & Findings for A Study to Detect Progression of Mass Effect From Unilateral Brain Lesions (NCT NCT04745884)

NCT ID: NCT04745884

Last Updated: 2026-02-06

Results Overview

Functional outcome was assessed using the Modified Rankin Scale (mRS) which assesses functional outcomes in patients recovering from strokes. It consists of a 7-point ordinal scale ranging from 0 to 6 where 0=no symptoms and 6=dead with higher scores indicating a worse functional outcome.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

6 participants

Primary outcome timeframe

3 months

Results posted on

2026-02-06

Participant Flow

Recruitment stopped because bilateral monitoring was proven not sufficiently reliable for investigation

Participant milestones

Participant milestones
Measure
Monitoring
Imaging guided by monitoring results Non-invasive bilateral monitoring of ICP waveform: Brain4care non-invasive bilateral monitoring of ICP waveform
Overall Study
STARTED
6
Overall Study
COMPLETED
3
Overall Study
NOT COMPLETED
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Monitoring
Imaging guided by monitoring results Non-invasive bilateral monitoring of ICP waveform: Brain4care non-invasive bilateral monitoring of ICP waveform
Overall Study
Excessive Signal Feedback-Uninterpretable Data
3

Baseline Characteristics

A Study to Detect Progression of Mass Effect From Unilateral Brain Lesions

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Monitoring
n=6 Participants
Imaging guided by monitoring results Non-invasive bilateral monitoring of ICP waveform: Brain4care non-invasive bilateral monitoring of ICP waveform
Region of Enrollment
United States
6 participants
n=41 Participants
Age, Continuous
50 years
STANDARD_DEVIATION 4 • n=41 Participants
Sex: Female, Male
Female
1 Participants
n=41 Participants
Sex: Female, Male
Male
5 Participants
n=41 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=41 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants
n=41 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=41 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=41 Participants
Race (NIH/OMB)
Asian
1 Participants
n=41 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=41 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=41 Participants
Race (NIH/OMB)
White
5 Participants
n=41 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=41 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=41 Participants

PRIMARY outcome

Timeframe: 3 months

Population: 1 patient was unable to be reached for follow up

Functional outcome was assessed using the Modified Rankin Scale (mRS) which assesses functional outcomes in patients recovering from strokes. It consists of a 7-point ordinal scale ranging from 0 to 6 where 0=no symptoms and 6=dead with higher scores indicating a worse functional outcome.

Outcome measures

Outcome measures
Measure
Monitoring
n=5 Participants
Imaging guided by monitoring results Non-invasive bilateral monitoring of ICP waveform: Brain4care non-invasive bilateral monitoring of ICP waveform
Functional Outcome
3 score on a scale
Interval 2.0 to 4.0

SECONDARY outcome

Timeframe: within ICU admission

Population: The BrainCare device was too sensitive to any movement including breathing. Due to the sensitivity of the device, zero ICP waveforms were detected. The waveforms were needed to measure this outcome, with the waveforms not showing up on the BrainCare device due to the sensitivity of the device, this outcome could not be measured.

Number of imaging scans

Outcome measures

Outcome data not reported

Adverse Events

Monitoring

Serious events: 0 serious events
Other events: 0 other events
Deaths: 2 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Alejandro Rabinstein, M.D.

Mayo Clinic

Phone: 507-284-4741

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place